Počet záznamů: 1  

Clinical adenoviral gene therapy for prostate cancer

  1. 1.
    SYSNO ASEP0351752
    Druh ASEPJ - Článek v odborném periodiku
    Zařazení RIVZáznam nebyl označen do RIV
    Poddruh JČlánek ve WOS
    NázevClinical adenoviral gene therapy for prostate cancer
    Tvůrce(i) Schenk, E. (NL)
    Essand, M. (SE)
    Bangma, Ch. H. (NL)
    Barber, Ch. (GB)
    Behr, J.-P. (FR)
    Briggs, S. (GB)
    Carlisle, R. (GB)
    Cheng, W.-S. (SE)
    Danielsson, A. (SE)
    Dautzenberg, I. J. C. (NL)
    Dzojic, H. (SE)
    Erbacher, P. (FR)
    Fisher, K. (GB)
    Frazier, A. (GB)
    Georgopoulos, L. J. (GB)
    Hoeben, R. (NL)
    Kochanek, S. (DE)
    Koppers-Lalic, D. (NL)
    Kraaij, R. (NL)
    Kreppel, F. (DE)
    Lindholm, L. (SE)
    Magnusson, M. (SE)
    Maitland, N. (GB)
    Neuberg, P. (GB)
    Nilsson, B. (SE)
    Ogris, M. (DE)
    Remy, J.-S. (FR)
    Scaife, M. (GB)
    Schooten, E. (NL)
    Seymour, L. (SE)
    Totterman, T. (SE)
    Uil, T. G. (NL)
    Ulbrich, Karel (UMCH-V) RID
    Veldhoven-Zweistra, J. L. M. (NL)
    de Vrij, J. (NL)
    van Weerden, W. (NL)
    Wagner, E. (DE)
    Willemsen, R. (NL)
    Zdroj.dok.Human Gene Therapy. - : MARY ANN LIEBERT INC - ISSN 1043-0342
    Roč. 21, č. 7 (2010), s. 807-813
    Poč.str.7 s.
    Jazyk dok.eng - angličtina
    Země vyd.US - Spojené státy americké
    Klíč. slovaadenovirus ; gene delivery ; prostate cancer
    Vědní obor RIVCD - Makromolekulární chemie
    UT WOS000279596700003
    DOI10.1089/hum.2009.206
    AnotaceProstate cancer is at present the most common malignancy in men in the Western world. When localized, this disease can be treated by curative therapy such as surgery and radiotherapy. Unfortunately, for advanced stage of the disease only palliative treatment is available. Therefore, there is a clinical need for new treatment modalities that can, on the one hand, enhance the cure rate of primary therapy for localized prostate cancer and, on the other hand, improve the treatment of metastasized disease. Gene therapy is now being explored in the clinic as a treatment option for the various stages of prostate cancer. Current clinical experiences are based predominantly on trials with adenoviral vectors. As the first of a trilogy of reviews on the state of the art and future prospects of gene therapy in prostate cancer, this review focuses on the clinical experiences and progress of adenovirus-mediated gene therapy for this disease.
    PracovištěÚstav makromolekulární chemie
    KontaktEva Čechová, cechova@imc.cas.cz ; Tel.: 296 809 358
    Rok sběru2011